Outlook Therapeutics (OTLK) Current Taxes (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Current Taxes of $302000.0 for Q1 2026, down 83.73% year-over-year from $1.9 million in Q1 2025, and little changed quarter-over-quarter from $302000.0 in Q4 2025.
Outlook Therapeutics (OTLK) Current Taxes (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Current Taxes for 12 consecutive years, with $302000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Taxes fell 83.73% year-over-year to $302000.0; the TTM figure through Mar 2026 stood at $302000.0 (down 83.73% YoY), while the FY2025 annual figure was $302000.0, down 83.73% from the prior year.
- Current Taxes steadied at $302000.0 in Q1 2026 per OTLK's latest filing, from $302000.0 in the prior quarter.
- Across five years, Current Taxes topped out at $1.9 million in Q1 2022 and bottomed at $302000.0 in Q3 2025.
- Historically, Current Taxes has averaged $1.6 million across 5 years, with a median of $1.9 million in 2022.
- Annual changes were most pronounced in 2022 — Current Taxes changed 0.0% — and 2025, when it plunged 83.73%.
- Outlook Therapeutics' Current Taxes stood at $1.9 million in 2022, then changed by 0.0% to $1.9 million in 2023, then changed by 0.0% to $1.9 million in 2024, then slumped by 83.73% to $302000.0 in 2025, then changed by 0.0% to $302000.0 in 2026.
- Business Quant data shows OTLK's Current Taxes at $302000.0 in Q1 2026, $302000.0 in Q4 2025, and $302000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 49.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 76.32 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.36 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | 302,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 302,000.00 |
| Dec 31, 2025 | 302,000.00 |
| Sep 30, 2025 | 302,000.00 |
| Jun 30, 2025 | 1.86 Mn |
| Mar 31, 2025 | 1.86 Mn |
| Dec 31, 2024 | 1.86 Mn |
| Sep 30, 2024 | 1.86 Mn |
| Jun 30, 2024 | 1.86 Mn |
| Mar 31, 2024 | 1.86 Mn |
| Dec 31, 2023 | 1.86 Mn |
| Sep 30, 2023 | 1.86 Mn |
| Jun 30, 2023 | 1.86 Mn |
| Mar 31, 2023 | 1.86 Mn |
| Dec 31, 2022 | 1.86 Mn |
| Sep 30, 2022 | 1.86 Mn |
| Jun 30, 2022 | 1.86 Mn |
| Mar 31, 2022 | 1.86 Mn |
| Dec 31, 2021 | 1.86 Mn |
| Sep 30, 2021 | 1.86 Mn |
| Jun 30, 2021 | 1.86 Mn |